Federal Circuit affirms Humira licence decision

Yesterday, the US Court of Appeals for the Federal Circuit backed a lower court’s decision to dismiss a declaratory judgment lawsuit filed by AbbVie over its drug Humira (adalimumab).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Federal Circuit denies further term extensions to shoulder surgery patentee

9 February 2021 The US Court of Appeals for the Federal Circuit has upheld a decision by a district court that an inventor cannot further extend his shoulder surgery patent after already being granted a term adjustment period by the US Patent and Trademark Office.

Americas

AbbVie and Amgen settle Humira clash

29 September 2017 AbbVie has settled its patent dispute over Amgen’s proposed biosimilar for Humira (adalimumab), a drug used to treat multiple types of arthritis as well as psoriasis.

Americas

AbbVie Humira patent invalidated by PTAB

19 May 2017 AbbVie has lost in an inter partes review (IPR) of its rheumatoid arthritis drug Humira.

More on this story

Americas

Federal Circuit denies further term extensions to shoulder surgery patentee

Americas

AbbVie and Amgen settle Humira clash

29 September 2017 AbbVie has settled its patent dispute over Amgen’s proposed biosimilar for Humira (adalimumab), a drug used to treat multiple types of arthritis as well as psoriasis.

Americas

AbbVie Humira patent invalidated by PTAB

19 May 2017 AbbVie has lost in an inter partes review (IPR) of its rheumatoid arthritis drug Humira.

More on this story

Americas

Federal Circuit denies further term extensions to shoulder surgery patentee

Americas

AbbVie and Amgen settle Humira clash

29 September 2017 AbbVie has settled its patent dispute over Amgen’s proposed biosimilar for Humira (adalimumab), a drug used to treat multiple types of arthritis as well as psoriasis.

Americas

AbbVie Humira patent invalidated by PTAB

19 May 2017 AbbVie has lost in an inter partes review (IPR) of its rheumatoid arthritis drug Humira.